Exp Clin Endocrinol Diabetes 2025; 133(04): 191-196
DOI: 10.1055/a-2500-1124
German Diabetes Association: Clinical Practice Guidelines

Nephropathy in Diabetes

Ludwig Merker
1   Diabetology Neanderthal, Erkrath, Germany
,
Thomas Ebert
2   Department of Internal Medicine III – Endocrinology, Nephrology and Rheumatology, University Hospital Leipzig, Leipzig, Germany
,
Erwin Schleicher
3   Institute for Clinical Chemistry and Pathobiochemistry – Central Laboratory, University Hospital Tübingen, Tübingen, Germany
,
Berend Isermann
4   Institute of Laboratory Medicine, Clinical Chemistry and Molecular Diagnostics, University Hospital Leipzig, Leipzig, Germany
,
Martina Guthoff
5   Department of Internal Medicine IV – Diabetology, Endocrinology, Nephrology, University Hospital Tübingen, Germany
› Author Affiliations
Preview
Notice of update

The DDG clinical practice guidelines are updated regularly during the second half of the calendar year. Please ensure that you read and cite the respective current version.

UPDATES TO CONTENT AND DIFFERENT RECOMMENDATIONS COMPARED TO THE PREVIOUS YEAR’S VERSION

Change 1:

Therapy section on targeted drug-based progression inhibition updated

Reason:

New approvals in Germany as well as more recent data on GLP-1 receptor agonists

Supporting reference:

[1]

Change 2:

Overview of diagnostics and the resulting measures for people with chronic renal insufficiency

Reason:

New guidelines

Supporting reference:

[2]

Change 3:

Recommendations for the use of finerenone as a nonsteroidal mineralocorticoid receptor antagonist in type 2 diabetes and CRI

Reason:

New guidelines

Supporting reference:

[2] and [3]

Change 4:

Updated overview of the approval of antidiabetic drugs for chronic renal insufficiency in Germany

Reason:

New approvals in Germany, new therapy principles



Publication History

Article published online:
06 May 2025

© 2025. Thieme. All rights reserved.

Georg Thieme Verlag KG
Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany